Plain-English translation of NCT05894824 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a combination of two medications — Trastuzumab deruxtecan and Ramucirumab — to treat advanced stomach or junction-of-stomach cancer in patients whose cancer did not respond to or came back after their first treatment. The trial will first figure out the safest dose of this medication combination, then test how well it works and how tolerable it is for patients.
Many patients with advanced stomach cancer run out of good treatment options after their first attempt fails. This trial is exploring whether combining these two medications might offer a new hope for people in that situation.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the two medications on a regular schedule at the study center. The trial has two phases: in the first phase, doctors will carefully increase doses to find the safest amount; in the second phase, more patients will be treated at that safest dose while researchers monitor how well the treatment works. You will have regular blood tests, heart imaging, and physical exams to check your safety and how your cancer responds.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
South Korea